ORIG3N

About:

ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases.

Twitter/X: ORIG3N

Top Investors: Alexandria Venture Investments, LabCorp, Hatteras Venture Partners, Vectr, Mountain Group Capital

Description:

ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases with targets in heart, liver, and neurodegenerative indications. It was founded in 2014 and is based in Boston, Massachusetts.

Total Funding Amount:

$76.2M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Boston, Massachusetts, United States

Founded Date:

2014-04-10

Contact Email:

info(AT)orig3n.com

Founders:

Kate Blanchard, Robin Smith

Number of Employees:

11-50

Last Funding Date:

2020-09-09

IPO Status:

Private

Industries: